← All indications
Biliary Tract Neoplasms
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Subtype terms (2)
More specific conditions that are subtypes of Biliary Tract Neoplasms in the MeSH hierarchy.
- Bile Duct Neoplasms
154 drugs (84 approved, 70 experimental)
- Gallbladder Neoplasms
135 drugs (72 approved, 63 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (40)
- anlotinib
- atezolizumab
- becatecarin
- binimetinib
- durvalumab
- encorafenib
- fluorouracil
- paclitaxel
- pembrolizumab
- leucovorin
- niraparib
- nuc-1031
- trastuzumab
- carboplatin
- s-1
- bevacizumab
- futibatinib
- varlitinib
- capecitabine
- adebrelimab
- gimeracil
- oteracil
- cediranib
- oxaliplatin
- erlotinib
- tegafur
- ivosidenib
- levoleucovorin
- neratinib maleate
- fam-trastuzumab deruxtecan-nxki
- +10 more
Phase 2 trials (136)
- simvastatin
- merestinib
- abemaciclib
- rucaparib
- axitinib
- allogeneic natural killer cells
- autologous tumor infiltrating lymphocytes
- avelumab
- olaparib
- sorafenib
- bi 754091
- irinotecan
- certolizumab pegol
- cobimetinib
- devimistat
- dkn-01
- donafenib
- fulvestrant
- fruquintinib
- vismodegib
- trametinib
- lapatinib
- hydroxychloroquine
- ramucirumab
- nivolumab
- mitomycin
- ka2507
- lenvatinib
- load703
- regorafenib
- +106 more
Phase 1 trials (31)
- abgn-107
- Fosgemcitabine
- mkc1106
- ly3214996
- prostate specific membrane antigen
- il-2 expressing salmonella typhimurium
- pimitespib
- tocilizumab
- aflibercept
- psilocybin
- zkab001
- ceralasertib
- emavusertib
- mgd013
- so-c101
- ro7119929
- gq1001
- abbv-400
- ly3295668
- ava6000
- ct-0508
- ly3537982
- bl-m07d1
- pt886
- anti-cdh17 car-t cells
- anti-ex02 car t cells
- bl-m05d1
- zm008
- mbtc vax
- lncb74
- +1 more
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (24)
- AstraZeneca
- Merck Serono
- Helsinn
- Merck KGaA
- 3D Medicines
- German Research Foundation
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
- Case Western Reserve University
- Cancer Research Campaign
- Cancer Research UK
- University of London
- Kyoto University
- Southwest Oncology Group
- University of Toronto
- Kansai Hepatobiliary Oncology Group (KHBO)
- Hutchison MediPharma
- Tianjin Medical University
- SPARC
- J. W. Goethe University
- Moorgreen Hospital, Southampton
- Nucana
- Sungkyunkwan University
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (104)
- Incyte
- Spectrum Pharmaceuticals
- Daiichi Sankyo
- Seattle Genetics
- Eisai
- Celgene
- Shire
- Bristol-Myers Squibb
- Amgen
- Roche
- Merck
- Eli Lilly
- Genentech
- Genzyme
- Sanofi
- Sanofi-Synthelabo
- Ipsen
- AIO-Studien-gGmbH
- Baxalta
- Bayer
- BeOne Medicines
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- InnoPharmax Inc.
- Jeil Pharmaceutical Co., Ltd.
- Karus Therapeutics Limited
- Leap Therapeutics, Inc.
- Lexicon Pharmaceuticals
- RemeGen
- Sorrento Therapeutics, Inc.
- +74 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (2)